Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer (Review)

Experimental and Therapeutic Medicine

Volumn 2, Issue 2, 2011, Pages 167-172

  Ge, Zhicheng ^a,b   Sanders, Andrew J ^a   Ye, Lin ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Death decoy receptor 3; Death receptor 3

Indexed keywords

DEATH DECOY RECEPTOR 3; DEATH RECEPTOR 3; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CARCINOMA; CELLULAR DISTRIBUTION; HUMAN; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TISSUE DISTRIBUTION;

EID: 79551623546     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.206     Document Type: Review

References (93)

1. Kitson J, Raven T, Jiang YP, et al: A death-domain-containing receptor that mediates apoptosis. Nature 384: 372-375, 1996.
2. Marsters SA, Sheridan Jp, Donahue cJ, et al: APO-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. curr Biol 6: 1669-1676, 1996.
3. chinnaiyan AM, O'Rourke K, Yu GL, et al: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274: 990-992, 1996.
4. Kaplan MJ, ray D, Mo RR, Yung RL and Richardson Bc: TRAIL (Apo2 ligand) and TWEAK (APO3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 164: 2897-2904, 2000.
5. Kaptein A, Jansen M, Dilaver G, et al: Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMp (DR3). FEBS Lett 485: 135-141, 2000.
6. nakayama M, Ishidoh K, Kayagaki N, et al: Multiple pathways of TWEAK-induced cell death. J Immunol 168: 734-743, 2002.
7. Zhai Y, Nİ J, Jiang GW, et al: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189, 1999.
8. Migone TS, Zhang J, Luo X, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
9. Parr C, Gan CH, Watkins G and Jiang WG: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81, 2006.
10. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. cell 104: 487-501, 2001.
11. Muppidi JR, Tschopp J and Siegel RM: Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21: 461-465, 2004.
12. Wen L, Zhuang L, Luo X and Wei P: TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem 278: 39251-39258, 2003.
13. Gout S, Morin C, Houle F and Huot J: death receptor-3, a new E-selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res 66: 9117-9124, 2006.
14. pitti RM, Marsters SA, Lawrence DA, et al: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703, 1998.
15. Bai C, connolly B, Metzker ML, et al: Overexpression of M68/ DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97: 1230-1235, 2000.
16. Zhang J, Salcedo TW, Wan X, et al: Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest 107: 1459-1468, 2001.
17. Wu Y, Ian B, Sheng H, et al: Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J cancer 105: 724-732, 2003.
18. Hsu TL, chang YC, chen SJ, et al: Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 168: 4846-4853, 2002.
19. Hsu TL, Wu YY, Chang YC, et al: Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 175: 5135-5145, 2005.
20. Hsu MJ, Lin WW, Tsao WC, et al: Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp Cell Res 292: 241-251, 2004.
21. Wu SF, Liu TM, Lin YC, et al: immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J Leukoc Biol 75: 293-306, 2004.
22. Bodmer JL, Burns K, Schneider P, et al: TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity 6: 79-88, 1997.
23. Tartaglia LA, Ayres TM, Wong GH and Goeddel DV: A novel domain within the 55 kd TNF receptor signals cell death. Cell 74: 845-853, 1993.
24. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.
25. Tan KB, larrop J, Reddy M, et al: characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 35-46, 1997.
26. Haridas V, Shrivastava A, Su J, et al: VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18: 6496-6504, 1999.
27. Xiao Q, Hsu CY, Chen H, Ma X, Xu J and Lee JM: Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388: 913-920, 2005.
28. Zhai Y, Yu J, Iruela-Arispe L, et al: Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82: 131-136, 1999.
29. Chew LJ, Pan H, Yu J, et al: A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16: 742-744, 2002.
30. Lasky LA: Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 258: 964-969, 1992.
31. Higai K, Shimamura A and Matsumoto K: Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin Chim Acta 367: 137-143, 2006.
32. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D and Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9: 899-909, 1995.
33. Subramaniam M, Koedam JA and Wagner DD: Divergent fates of P-and E-selectins after their expression on the plasma membrane. Mol Biol Cell 4: 791-801, 1993.
34. Steegmaier M, Levinovitz A, Isenmann S, et al: The E-selectinligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 373: 615-620, 1995.
35. Constantin G: PSGL-1 as a novel therapeutic target. Drug News Perspect 17: 579-586, 2004.
36. Romano SJ and Slee DH: Targeting selectins for the treatment of respiratory diseases. Curr Opin Investig Drugs 2: 907-913, 2001.
37. Bock D, Philipp S and Wolff G: Therapeutic potential of selectin antagonists in psoriasis. Expert Opin Investig Drugs 15: 963-979, 2006.
38. Sfikakis PP and Mavrikakis M: Adhesion and lymphocyte costimulatory molecules in systemic rheumatic diseases. clin Rheumatol 18: 317-327, 1999.
39. Witz IP: Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res 130: 125-140, 2006.
40. Laferriere J, Houle F and Huot J: Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann NY Acad Sci 973: 562-572, 2002.
41. Witz IP: The involvement of selectins and their ligands in tumor-progression. Immunol Lett 104: 89-93, 2006.
42. Romano SJ: Selectin antagonists: therapeutic potential in asthma and COPD. Treat Respir Med 4: 85-94, 2005.
43. Mauri DN, Ebner R, Montgomery RI, et al: LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8: 21-30, 1998.
44. Harrop JA, McDonnell PC, Brigham-Burke M, et al: Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/ TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 273: 27548-27556, 1998.
45. Murphy M, Walter BN, Pike-Nobile L, et al: Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ 5: 497-505, 1998.
46. Stopfer P, Mannel DN and Hehlgans T: Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J Immunol 172: 7459-7465, 2004.
47. Yu P, Lee Y, Liu W, et al: Priming of naive T cells inside tumors leads to eradication of established tumors. Nat immunol 5: 141-149, 2004.
48. Tamada K, Shimozaki K, Chapoval AI, et al: LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 164: 4105-4110, 2000.
49. Yu P and Fu YX: Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev 19: 285-294, 2008.
50. Itoh N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991.
51. Suda T, Takahashi T, Golstein P and Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993.
52. Van Parijs L and Abbas AK: Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin immunol 8: 355-361, 1996.
53. Griffith TS and Ferguson TA: The role of FasL-induced apoptosis in immune privilege. Immunol Today 18: 240-244, 1997.
54. Muschen M, Moers C, Warskulat U, Even J, Niederacher D and Beckmann MW: CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 99: 69-77, 2000.
55. O'connell J, Bennett MW, O'Sullivan GC, et al: Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 186: 240-246, 1998.
56. Koyama S, Koike N and Adachi S: Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol 127: 20-26, 2001.
57. Bennett MW, O'Connell J, O'Sullivan GC, et al: The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160: 5669-5675, 1998.
58. Reimer T, Herrnring C, Koczan D, et al: FasL: Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 60: 822-828, 2000.
59. Li W, Zhang C, Chen C and Zhuang G: Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. cell Mol Immunol 4: 455-460, 2007.
60. Bu R, Borysenko CW, Li Y, Cao L, Sabokbar A and Blair HC: Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 33: 760-770, 2003.
61. Screaton GR, Xu XN, Olsen AL, et al: LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci USA 94: 4615-4619, 1997.
62. Wang EC, Kitson J, Thern A, Williamson J, Farrow SN and Owen MJ: Genomic structure, expression, and chromosome mapping of the mouse homologue for the WSL-1 (DR3, Apo3, TRAMP, LARD, TR3, TNFRSF12) gene. Immunogenetics 53: 59-63, 2001.
63. Eggert A, Grotzer MA, Zuzak TJ, Ikegaki N, Zhao H and Brodeur GM: Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. Eur J Cancer 38: 92-98, 2002.
64. Warzocha K, Ribeiro P, Charlot C, Renard N, Coiffier B and Salles G: A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin's lymphomas. Biochem Biophys Res Commun 242: 376-379, 1998.
65. Chen G and Luo D: Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India 21: 275-278, 2008.
66. Li L, Hu J, Zhao R and Yue Z: [Expression of DcR3 protein and its significance in laryngeal carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 21: 537-539, 2007.
67. Liang QL, Wang BR and Li GH: DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B 10: 675-682, 2009.
68. Ho CH, Chen CL, Li WY and Chen CJ: Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 30: 1443-1451, 2009.
69. Chen PH and Yang CR: Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphati-dylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 181: 8441-8449, 2008.
70. Macher-Goeppinger S, Aulmann S, Wagener N, et al: Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10: 1049-1056, 2008.
71. Li H, Zhang L, Lou H, et al: Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol 124: 282-287, 2005.
72. Simon I, Liu Y, Krall KL, et al: Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 106: 112-118, 2007.
73. Zhang L, Zhang Y, Yang X and Lv Z: Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells. cancer Invest 27: 163-170, 2009.
74. Hayashi S, Miura Y, Nishiyama T, et al: Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 56: 1067-1075, 2007.
75. Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS and Targan SR: The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 178: 4033-4038, 2007.
76. Wroblewski VJ, Witcher DR, Becker GW, et al: Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem Pharmacol 65: 657-667, 2003.
77. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and Kwon BS: A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274: 13733-13736, 1999.
78. Yang cR, Hsieh SL, Teng CM, Ho FM, Su WL and Lin WW: Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. cancer Res 64: 1122-1129, 2004.
79. Tian F, Liang PH and Li LY: Inhibition of endothelial progenitor cell differentiation by VEGI. Blood 113: 5352-5360, 2009.
80. Murtaza I, Adhami VM, Hafeez BB, Saleem M and Mukhtar H: Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer 125: 2465-2473, 2009.
81. Gill RM and Hunt JS: Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAp-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis. Am J pathol 165: 309-317, 2004.
82. Chen G and Luo D: Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. ups J Med Sci 113: 297-304, 2008.
83. Wu YL, Yu JX, Shen HW, Han B and Gao SL: [Clinical significance and correlation between elevated serum TR6 and lympho-metastasis in gastric cancer]. Zhonghua Wai Ke Za Zhi 41: 928-931, 2003.
84. Wu Y, Guo E, Yu J and Xie Q: High DcR3 expression predicts stage pN2-3 in gastric cancer. Am J Clin Oncol 31: 79-83, 2008.
85. Wu Y, Guo E, Yu J, Xie Q and Chen J: High DcR3 expression predicts stage pN2 in gastric cancer. Hepatogastroenterology 54: 2172-2176, 2007.
86. Roth W, Isenmann S, Nakamura M, et al: Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61: 2759-2765, 2001.
87. Shen HW, Gao SL, Wu YL and peng SY: Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 11: 5926-5930, 2005.
88. Chen G, Luo DZ, Wang Y, Liao ZL and Zhang MY: [Relationship between expression of decoy receptor 3 and apoptosis in hepato-cellular carcinoma]. Zhonghua Bing Li Xue Za Zhi 36: 113-117, 2007.
89. Chang YC, Hsu TL, Lin HH, et al: Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 75: 486-494, 2004.
90. Shi G, Wu Y, Zhang J and Wu J: Death decoy receptor TR6/ DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol 171: 3407-3414, 2003.
91. Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL and Li LY: The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol 179: 3742-3751, 2007.
92. Morishige T, Yoshioka Y, Inakura H, et al: Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy. Biomaterials 31: 3357-3363, 2010.
93. Wu CF, Ma ZS, Wang XL, et al: [Preparation and identification of monoclonal antibodies against human DcR3]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 24: 139-141, 2008.